I do not think there is anything wrong in venting a bit of frustration. One would expect that as MSB is so close to commercialising that the we should not be seeing these roller coaster price movements. While the Prof has been advocating non dilution of shares, the piece meal capital raising does dilute and should they have raised sufficient capital at one go that could have eliminated the frequent fluctuations which have been quite substantial. Unlike the other Australian Biotechs which have partners who stay and each time there is a bit of news the shares move upwards eg. CYP, though years behind MSB in commercialisation has an almost similar price.
Many on HC have bought shares in at levels which was thought to be low enough only to see it going lower. Depending on financial circumstances, some had to cut losses and have reason to be bitter.
Many have exhausted their funds and unable to buy further and therefore would like to see some price stability before the anticipated big rise.
Unfortunately with Biotechs there is always an element of risk and MSB has had its fair share of problems and while my personal view is that this stock has the potential to be a blockbuster we just have to be a bit more patient and weather the storm.
Add to My Watchlist
What is My Watchlist?
